Cannabidiol Administered During Peri-Adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia Fernanda F. Peres, Mariana C. Diana, Raquel Levin, Mayra A. Suiama, Valéria Almeida, Ana M. Vendramini, Camila M. Santos, Antônio W. Zuardi, Jaime E. C. Hallak, José A. Crippa and Vanessa C. Abílio Frontiers in Pharmacology, 2018, 9, article 901. Doi : 10.3389/fphar.2018.00901 Schizophrenia is considered a debilitating neurodevelopmental psychiatric disorder and its pharmacotherapy remains problematic without recent major advances. The development of interventions able to prevent the emergence of schizophrenia would therefore represent an enormous progress. Here, we investigated whether treatment with cannabidiol (CBD – a compound of Cannabis sativa that [...]
Lire la suiteCannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression. Case Report Clarissa Laczkovics · Oswald D. Kothgassner · Anna Felnhofer · Claudia M. Klier Neuropsychiatrie, 2020, 4 p. Doi : 10.1007/s40211-020-00334-0 Summary In this report, we present a case of a 16,9- year-old patient with multiple substance use disorder (cannabis, MDMA, cocaine, ecstacy), severe depression, social phobia and narcissistic personality disorder. We administered Cannabidiol (CBD) capsules in different dosages (starting dosage 100 mg up to 600 mg over 8 weeks) after unsuccessful treatment with antidepressants. CBD was a safe and well tolerated medication for this patient. Upon treatment with CBD and [...]
Lire la suiteCannabis and the developing brain : Insights from behavior Viviana Trezza, Vincenzo Cuomo, Louk J.M.J. Vanderschuren European Journal of Pharmacology, 2008, 585, 441-452. Doi : 10.1016/j.ejphar.2008.01.058 A B S T R A C T The isolation and identification, in 1964, of delta-9-tetrahydrocannabinol (THC), the primary psycho-active compound in cannabis, opened the door to a whole new field of medical research. The exploration of the therapeutic potential of THC and other natural and synthetic cannabinoid compounds was paralleled by the discovery of the endocannabinoid system, comprising cannabinoid receptors and their endogenous ligands, which offered exciting new insights into brain function. Besides its well-known involvement in specific [...]
Lire la suiteHow Adolescents with Autism Spectrum Disorder (ASD) Spontaneously Attend to Real-World Scenes : Use of a Change Blindness Paradigm Michal Hochhauser, Adi Aran, Ouriel Grynszpan Journal of Autism and Developmental Disorders, 2018, 48, 502–510 DOI 10.1007/s10803-017-3343-6 https://www.researchgate.net/publication/320647151_How_Adolescents_with_Autism_Spectrum_Disorder_ASD_Spontaneously_Attend_to_Real-World_Scenes_Use_of_a_Change_Blindness_Paradigm [accessed Jul 16 2019]. Abstract Visual attention of adolescents with autism spectrum disorder (ASD) was assessed using a change blind-ness paradigm. Twenty-five adolescents with ASD aged 12–18 years and 25 matched typically developing (TD) adolescents viewed 36 pairs of digitized real-world images. Each pair of images was displayed in a ‘flicker paradigm’ whereby a particular item alternately appeared and disappeared. This item was either a central or a marginal [...]
Lire la suiteAwareness of Emotional Expressions in Cannabis Users : An Event-Related Potential Study Robert D. Torrence, Donald C. Rojas and Lucy J. Troup Frontiers in Psychology, February 2019 | Volume 10 | Article 69 ORIGINAL RESEARCH doi: 10.3389/fpsyg.2019.00069 Abstract Cannabis use has been associated with anxiogenic effects when used in low frequency for a short duration, but cannabis can also have anxiogenic effects when used heavily for a long duration. Animal studies have indicated the neurobiological mechanisms related to cannabis and anxiety; however, research has been limited on the related neurocognitive mechanisms. Previous research has indicated that cannabis use is associated with alterations in event-related potentials (ERPs). [...]
Lire la suiteLes cannabinoïdes dans l’Autisme : Dr Christian Sueur GRECC (Groupe de Recherches et D’Etudes Cliniques sur les Cannabinoïdes) Version actualisée juin 2019 L’autisme est une pathologie, ou plutôt un trouble majeur du développement psycho-neuro-développemental, à l’étiologie complexe et multifactorielle ; rentrent vraisemblablement en interaction, pour produire un trouble du spectre autistique, aussi bien des facteurs psychologique interactionnels précoces, qu’un terrain de fragilité ou de prédisposition génétique, à l’origine d’anomalies neurophysiologiques du développement de la connectique neuronale. Depuis près d’une vingtaine d’année, les cannabinoïdes représente progressivement une nouvelle voie d’approche thérapeutique des autismes les plus sévères. Certains parents, surtout aux USA[1], ont adopté depuis le début [...]
Lire la suiteADDICTIONS & troubles psychiatriques, REPERES Fédération Addiction, mai 2019 Avant-Propos L’association entre les pathologies addictives et psychiatriques est une source majeure de préoccupation et de difficultés pour les professionnels et les équipes des deux champs mais aussi et avant tout pour les personnes concernées et leur entourage, avec une qualité de vie fortement altérée. Ces comorbidités, ces pathologies associées ou duelles, selon les qualifications, sont en effet difficiles à repérer et à prendre en charge, chaque filière de soins, psychiatrique ou addictologique, ayant tendance à concentrer son attention et ses interventions sur la pathologie de son domaine d’expertise. Leur pronostic est péjoratif, l’évolution [...]
Lire la suiteRegular cannabis use is associated with altered activation of central executive and default mode networks even after prolonged abstinence in adolescent users : Results from a complementary meta-analysis Grace Blest-Hopley, Vincent Giampietro and Sagnik Bhattacharyya Neuroscience & Biobehavioral Reviews, 2019, 96, 45–55. doi: 10.1016/j.neubiorev.2018.10.026: 10.1016/j.neubiorev.2018.10.026 PMCID: PMC6331661 PMID: 30395923 Abstract Whether the effects of cannabis use on brain function persist or recover following abstinence remains unclear. Therefore, using meta-analytic techniques, we examined whether functional alterations measured using fMRI persist in cannabis users abstinent for over 25 days (or 600 h) as evidence suggests that the effects on cognitive performance no longer persist beyond this period. Systematic literature search [...]
Lire la suiteCannabidiol as a suggested candidate for treatment of autism spectrum disorder. POLEG S., GOLUBCHIK P., OFFEN D., WEIZMAN A. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 8, 89, 90-96. doi: 10.1016/j.pnpbp.2018.08.030 Abstract Autism Spectrum Disorder (ASD) is characterized by persistent deficits in social communication, restricted and repetitive patterns of behavior, interests, or activities and often intellectual disabilities. ASD has a number of prevalent co-morbidities, such as sleep disorders, attention deficit/hyperactivity disorder and epilepsy. No effective treatment for the core symptoms of ASD is currently available. There is increasing interest in cannabinoids, especially cannabidiol (CBD), as monotherapy or add-on treatment for the core symptoms and co-morbidities [...]
Lire la suiteCannabis Robert Hämmig, Ulrich W. Preuss und Michael Soyka January 2019 DOI: 10.1016/B978-3-437-23021-9.00009-6 Kernaussagen ● Die Cannabispflanze, welche die Menschheit seit Jahrtausenden begleitet, wird vi elfältig genutzt: ○ als Lieferant für Fasern zur Herstellung von Tüchern, Schnüren, Seilen und Papier, ○ als Nahrungsmittel (Samenkörner und Öl), ○ als Medizin für Mensch und Tier sowie als Genussmittel. ● Im 19. Jh. hielt Cannabis Einzug in die moderne westliche Medizin und wurde auch als „Freizeitdroge“ genutzt. Aus dieser Zeit stammen detaillierte phänomenologische Bes chreibungen der Effekte. Noch blieb aber der Wirkmechanismus völlig unklar. ● Die erste Hälfte des 20. Jh. ist das „dunkle Zeitalter“ des Cannabis, in dem das Fors chungsinteresse erlahmte. [...]
Lire la suite